Revolution Medicines Inc. (NASDAQ:RVMD) shares are up during Monday’s premarket session following positive topline results from its Phase 3 RASolute 302 clinical trial evaluating daraxonrasib for meta[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.
